Regeneron Pharmaceuticals Inc. ‘s stock REGN slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.Net income tumbled by 12% to $10.09 a ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it ...

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago ...

Regeneron’s financial results also note that revenues from its collaboration with Sanofi increased by 14% to $910 million because of growing profits from antibody commercialization. As sales ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...